WO2014031872A3 - Small molecule inhibitors for treating parasitic infections - Google Patents

Small molecule inhibitors for treating parasitic infections Download PDF

Info

Publication number
WO2014031872A3
WO2014031872A3 PCT/US2013/056219 US2013056219W WO2014031872A3 WO 2014031872 A3 WO2014031872 A3 WO 2014031872A3 US 2013056219 W US2013056219 W US 2013056219W WO 2014031872 A3 WO2014031872 A3 WO 2014031872A3
Authority
WO
WIPO (PCT)
Prior art keywords
small molecule
molecule inhibitors
parasitic infections
treating parasitic
treating
Prior art date
Application number
PCT/US2013/056219
Other languages
French (fr)
Other versions
WO2014031872A2 (en
Inventor
Benito Munoz
Sivaraman Dandapani
Ivan T. JEWETT
Sebastian LE QUEMENT
Andrew Germain
Jean-Charles MARIE
Byung-Chul Suh
Original Assignee
The Broad Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Broad Institute, Inc. filed Critical The Broad Institute, Inc.
Publication of WO2014031872A2 publication Critical patent/WO2014031872A2/en
Publication of WO2014031872A3 publication Critical patent/WO2014031872A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/18—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/22—Eight-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

The invention relates to a compound of Formula I or a pharmaceutically acceptable ester, salt, prodrug or metabolite thereof.
PCT/US2013/056219 2012-08-23 2013-08-22 Small molecule inhibitors for treating parasitic infections WO2014031872A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261692661P 2012-08-23 2012-08-23
US61/692,661 2012-08-23
US201261721804P 2012-11-02 2012-11-02
US61/721,804 2012-11-02

Publications (2)

Publication Number Publication Date
WO2014031872A2 WO2014031872A2 (en) 2014-02-27
WO2014031872A3 true WO2014031872A3 (en) 2014-04-24

Family

ID=50150496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/056219 WO2014031872A2 (en) 2012-08-23 2013-08-22 Small molecule inhibitors for treating parasitic infections

Country Status (1)

Country Link
WO (1) WO2014031872A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903220C (en) 2013-03-15 2023-01-24 Qing Xu Aldehyde compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
UA123810C2 (en) 2017-01-23 2021-06-02 Цадент Терапеутікс, Інк. Potassium channel modulators
RU2764243C2 (en) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Heterocyclic compounds as pad inhibitors
CA3076476A1 (en) 2017-10-18 2019-04-25 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
CA3080677A1 (en) 2017-11-06 2019-05-09 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
EP3704120B1 (en) 2017-11-24 2024-03-06 Jubilant Episcribe LLC Heterocyclic compounds as prmt5 inhibitors
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
CN112105610B (en) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
MX2021003158A (en) 2018-09-18 2021-07-16 Nikang Therapeutics Inc Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors.
TW202322824A (en) 2020-02-18 2023-06-16 美商基利科學股份有限公司 Antiviral compounds
CN117120444A (en) 2021-04-16 2023-11-24 吉利德科学公司 Method for preparing carbanucleoside using amide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080712A2 (en) * 2009-01-06 2010-07-15 Dana Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
WO2011025969A1 (en) * 2009-08-27 2011-03-03 The U.S.A., As Represented By The Secretary, Dept. Of Health And Human Services Compounds that treat malaria and prevent malaria transmission

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080712A2 (en) * 2009-01-06 2010-07-15 Dana Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
WO2011025969A1 (en) * 2009-08-27 2011-03-03 The U.S.A., As Represented By The Secretary, Dept. Of Health And Human Services Compounds that treat malaria and prevent malaria transmission

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHOU DANNY HUNG-CHIEH ET AL.: "Synthesis of a Novel Suppressor of (beta-Cell Apoptosis via Diversity-Oriented Synthesis.", ACS MEDICINAL CHEMISTRY LETTERS, vol. 2, no. 9, 2011, pages 698 - 702 *

Also Published As

Publication number Publication date
WO2014031872A2 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
WO2014031872A3 (en) Small molecule inhibitors for treating parasitic infections
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
EA201590224A1 (en) IMIDAZOTRIASINCARBONITRILE USED AS KINASE INHIBITORS
CR20130470A (en) QUINASE INHIBITORS RELATED TO PIRROLO [2,3-d] PYRIMIDINE THROMPOMIOSINE
IN2014CN03803A (en)
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
WO2012106534A3 (en) Hiv integrase inhibitors
UA107954C2 (en) Substituted pyrrolidin-2-carboxamide
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
IN2015DN00598A (en)
MX361499B (en) Deuterated baricitinib.
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
EA201591634A1 (en) DIHYDROPYRIDOPYRIMIDINE COMPOUNDS
RS54730B1 (en) Inhibitors of beta-secretase
JO3577B1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of sglt
MX345780B (en) Tricyclic gyrase inhibitors.
RS54526B1 (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
EA201592268A1 (en) DIHYDROPYRIDINONE INHIBITORS MGAT2
UA113086C2 (en) PRAZOLE COMPOUNDS AS SGLT1 INHIBITORS
CR20150325A (en) TRICYCLE COMPOUNDS TO INHIBIT THE CFTR CHANNEL
WO2010123545A3 (en) Angiogenesis inhibitors
WO2012154879A3 (en) Autophagy inhibitors
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
WO2013062332A3 (en) Vascular anti-aging composition including syringaresinol

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13831409

Country of ref document: EP

Kind code of ref document: A2